tradingkey.logo

CorMedix Inc

CRMD
查看詳細走勢圖
6.795USD
+0.085+1.27%
交易中 美東報價延遲15分鐘
538.58M總市值
3.00本益比TTM

CorMedix Inc

6.795
+0.085+1.27%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+1.27%

5天

+8.72%

1月

-4.70%

6月

-42.66%

今年開始到現在

-41.57%

1年

+0.82%

查看詳細走勢圖

TradingKey CorMedix Inc股票評分

單位: USD 更新時間: 2026-03-27

操作建議

CorMedix Inc當前公司基本面數據相對非常健康,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在藥品行業排名40/157位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為14.57。中期看,股價處於下降通道。近一個月,市場表現較差,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

CorMedix Inc評分

相關信息

行業排名
40 / 157
全市場排名
121 / 4542
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

CorMedix Inc亮點

亮點風險
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
業績轉盈
公司業績轉盈,最新年度盈利美元
估值合理
公司最新PE估值2.96,處於3年歷史合理位
機構加倉
最新機構持股43.86M股,環比增加0.02%
PRFDX持倉
明星投資者PRFDX持倉,最新持倉6.95K股
活躍度增加
近期活躍度增加,過去20天平均換手率2.50

分析師目標

基於 7 分析師
買入
評級
14.571
目標均價
+117.48%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

CorMedix Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

CorMedix Inc簡介

CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
公司代碼CRMD
公司CorMedix Inc
CEOTodisco (Joseph)
網址https://cormedix.com/
KeyAI